Category: Press Releases
October 31, 2019 | Press Releases
Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities
FARMINGTON, Conn., October 31, 2019 – Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Sinclair, to the Rallybio team. Specifically, Dr. Hayward will focus on further building Rallybio’s portfolio and Ms. Sinclair will be focused on new product commercial planning including diagnostic and patient access approaches to support the portfolio. These leadership appointments further advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. Amanda Hayward, PhD
September 12, 2019 | Press Releases
Rallybio Broadens Team Capabilities with Addition of Douglas Sheridan, PhD
FARMINGTON, Conn.– (BUSINESS WIRE)– Rallybio LLC, a development-stage biotechnology company, today announced that it has broadened its drug development capabilities with the addition of Douglas Sheridan, PhD. Dr. Sheridan, a seasoned R&D leader, has significant drug development experience, including discovery, strategic planning and clinical program management. He will help advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
August 8, 2019 | Press Releases
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
January 3, 2019 | Press Releases
Rallybio Further Strengthens Leadership Team with Addition of Steven Ryder
R&D Executive with Proven Track Record in the Biopharmaceutical Industry
October 2, 2018 | Press Releases
FierceBiotech Names Rallybio as One of its “Fierce 15” Biotech Companies of 2018
Award recognizes Rallybio as being among “the most promising private biotech startups”
August 7, 2018 | Press Releases
Rallybio Further Expands Drug Acquisition and Development Capabilities
Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities
July 10, 2018 | Press Releases
Rallybio Expands Drug Acquisition and Development Capabilities
Rallybio Expands Drug Acquisition and Development Capabilities with Addition of Veteran Industry Executives Zubin Bhagwagar, MD, PhD and Haren Vasavada, PhD, join Rallybio to identify and advance early-stage assets into clinical development
April 24, 2018 | Press Releases
Rallybio Completes $37.0M Series A Financing
FARMINGTON, CT, April 25, 2018 – Rallybio, LLC, a biotechnology company established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders, today announced that it has secured $37.0 million in Series A funding. 5AM Ventures, Canaan Partners, and New Leaf Venture Partners led the financing, with additional public-sector participation from Connecticut Innovations.